1723 – Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia

Page last updated: 08 July 2022

Application Detail

Description of Medical Service

Brexucabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.

Description of Medical Condition

Acute lymphoblastic leukaemia is a blood cancer that appears suddenly and grows rapidly. It starts when immature white blood cells called blasts become cancerous.

Reason for Application

Highly Specialised Therapy - National Health Reform Agreement

Medical Service Type

Therapeutic technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Form

Application Form (PDF 1044 KB)
Application Form (Word 787 KB)

Consultation Survey

Consultation Survey (PDF 323 KB)
Consultation Survey (Word 72 KB)

PASC Consultation
Expedited – Bypassing PASC

MSAC Consultation
MSAC consultation input must be received by no later than Friday, 7 October 2022 for it to be considered by MSAC at its November 2022 meeting.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

Expedited – Bypassing PASC

ESC

6-7 October 2022

MSAC

24-25 November 2022